- CEO
- Shanwei Zhang
- Full Time Employees
- 2,740
- Sector
- Transportation
- Industry
- Air freight/Couriers
- Address
- No. 71, Renmin Road Dalian LI China 116001
- IPO Date
- Aug 19, 1996
- Business
- Liaoning Cheng Da Co., Ltd. (600739.SS) is a diversified state-owned conglomerate primarily engaged in supply chain trade, biopharmaceuticals, financial investment, and energy development; its core products and services encompass import and export trading of textiles, garments, bulk commodities including coal, steel, aquatic and agricultural products; biological vaccines such as rabies vaccines for human use and research into bivalent hemorrhagic fever with renal syndrome vaccines, meningococcal polysaccharide conjugate vaccines, tetravalent influenza virus split vaccines, Haemophilus influenzae type B conjugate vaccines, and inactivated hepatitis A vaccines; financial services through investments in securities, insurance, funds, and enterprises like GF Securities and China Insurance; energy projects involving shale oil mining, production, and sales; as well as pharmacy chain operations, property leasing, warehousing, and retail distribution of consumer goods such as chemical products, edible oils, electronic products, construction materials, and health products.
The company operates across China and internationally in regions including the Americas, Africa, Europe, Oceania, and Asia, with subsidiaries and affiliates such as Liaoning Chengda Biotechnology Co., Ltd., Liaoning Chengda International Trade Co., Ltd., Xinjiang Chengda Baoming Energy Co., Ltd., and Chengda Fangyuan Pharmaceutical Chain Investment Co., Ltd.; it targets diverse customer segments from international trade partners and healthcare providers to financial institutions and energy consumers.
Founded in 1991 as Liaoning Province Needle Cotton Wool Fabric Import and Export Company and headquartered at Chengda Building, No. 71 Renmin Road, Dalian, Liaoning Province, China, the company restructured into its current form in 1993 and listed on the Shanghai Stock Exchange in 1996.
In recent developments, Liaoning Cheng Da completed the issuance of RMB 1.8 billion in exchangeable corporate bonds and plans a non-public issuance of up to RMB 5 billion in exchangeable CSI Enterprise bonds; its subsidiary Chengda Biotech signed a 2025 cooperation agreement with Zhongke Zidong Taichu (Beijing) Technology Co., Ltd. to establish an AI+ Vaccine Research and Development Joint Laboratory, focusing on data integration, technical research, service empowerment, and ecological construction; Gortune Investment obtained controlling interest through a board election on February 28, 2025, holding 15.30% of shares; and Shaoguan Gaoteng Enterprise Management Co., Ltd. proposed acquiring a 44.2% stake in Liaoning Chengda Biotechnology Co., Ltd. for CNY 4.7 billion.